KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 597.2 USD | -0.31% | +3.33% | +12.50% | 11.69% | ||
| 26.17 USD | -0.19% | +5.27% | -14.17% | 11.15% | ||
| 55.67 USD | -2.26% | +3.96% | -11.07% | 8.55% | ||
| 23.79 USD | -1.33% | +5.55% | -12.60% | 8.03% | ||
| 3.58 USD | -1.65% | -1.92% | -37.52% | 6.97% | ||
| 3.34 USD | -3.47% | +23.25% | -0.60% | 4.87% | ||
| 5.89 USD | -1.83% | +5.94% | -41.86% | 4.83% | ||
| 164.3 USD | +0.33% | +2.45% | +6.04% | 4.81% | ||
| 7.04 USD | +4.14% | +23.08% | -20.54% | 4.71% | ||
| 6.38 USD | +2.41% | +0.31% | -54.23% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
